World Journal of Anemia

Register      Login

VOLUME 2 , ISSUE 3and4 ( July-December, 2018 ) > List of Articles


Iron-deficiency Anemia and Chronic Kidney Disease: An Overview

Richa Saxena, Garima Sharma, Nikhita Gulati

Keywords : Anemia, Chronic kidney disease, Hemoglobin, Hepcidin, Iron deficiency, Iron loss

Citation Information : Saxena R, Sharma G, Gulati N. Iron-deficiency Anemia and Chronic Kidney Disease: An Overview. World J Anemia 2018; 2 (3and4):85-89.

DOI: 10.5005/jp-journals-10065-0037

License: CC BY-NC 4.0

Published Online: 01-12-2018

Copyright Statement:  Copyright © 2018; Jaypee Brothers Medical Publishers (P) Ltd.


Anemia is known to be a common and clinically important cause of chronic kidney disease (CKD). With progression of CKD, various factors can be attributed to reduction in hemoglobin (Hb) levels. However, reduced production of erythropoietin (EPO) due to impaired functioning of kidneys remains the central cause. The most effective treatment of anemia associated with CKD involves iron replacement and erythropoietic-stimulating agents (ESAs). Diagnosis of iron-deficiency anemia (IDA) in CKD patients is complicated due to the relatively poor predictive ability of routine serum iron indices such as ferritin and transferrin saturation. Invasive methods such as bone marrow iron stores or erythropoietic response to supplemental iron for detection of iron deficiency serve as the gold standard and are required for confirmation of diagnosis.

PDF Share
  1. Gafter-Gvili A, Schechter A, Rozen-Zvi B. Iron deficiency anemia in chronic kidney disease. Acta Haematol 2019;142(1):44–50. DOI: 10.1159/000496492.
  2. Aoun M, Karam R, Sleilaty G, et al. Iron deficiency across chronic kidney disease stages: Is there a reverse gender pattern? PLoS One 2018;13(1):e0191541. DOI: 10.1371/journal.pone.0191541.
  3. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol 2008;3(6):1691–1701. DOI: 10.2215/CJN.01070308.
  4. Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009;75(9):976–981. DOI: 10.1038/ki.2009.21.
  5. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010;55(4): 726–741. DOI: 10.1053/j.ajkd.2009.12.030.
  6. World Health Organization technical report series No. 405: nutritional anemias—report of a WHO Scientific Group. Geneva: WHO; 1968.
  7. US Renal Data System. Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2008.
  8. Global Burden of Disease 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390(10100): 1211–1259. DOI: 10.1016/S0140-6736(17)32154-2.
  9. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011;80(1):17–28. DOI: 10.1038/ki.2010.483.
  10. Khan SS, Kazmi WH, Abichandani R, et al. Health care utilization among patients with chronic kidney disease. Kidney Int 2002;62(1):229–236. DOI: 10.1046/j.1523-1755.2002.00432.x.
  11. NIH: Department of Health and Human Services. (2014). Anemia in Chronic Kidney Disease. [online]. Available from [Last accessed December, 2019].
  12. Atkinson MA, Warady BA. Anemia in chronic kidney disease. Pediatr Nephrol 2018;33(2):227–238. DOI: 10.1007/s00467-017-3663-y.
  13. Warner MJ, Kamran MT. Anemia, Iron Deficiency. Treasure Island (FL): StatPearls Publishing; 2019.
  14. Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci 2014;19(2):164–174.
  15. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 2001;98(15):8780–8785. DOI: 10.1073/pnas.151179498.
  16. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306(5704):2090–2093. DOI: 10.1126/science.1104742.
  17. Mazur A, Feillet-Coudray C, Romier B, et al. Dietary iron regulates hepatic hepcidin 1 and 2 mRNAs in mice. Metabolism 2003;52(10):1229–1231. DOI: 10.1016/S0026-0495(03)00277-4.
  18. Shah YM, Xie L. Hypoxia-inducible factors link iron homeostasis and erythropoiesis. Gastroenterology 2014;146(3):630–642. DOI: 10.1053/j.gastro.2013.12.031.
  19. Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 2008;111(2):924–931. DOI: 10.1182/blood-2007-07-100677.
  20. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101(7):2461–2463. DOI: 10.1182/blood-2002-10-3235.
  21. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110(7):1037–1044. DOI: 10.1172/JCI0215686.
  22. Zaritsky J, Young B, Wang HJ, et al. Hepcidin—a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009;4(6):1051–1056. DOI: 10.2215/CJN.05931108.
  23. Kato A, Tsuji T, Luo J, et al. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 2008;28(1):115–121. DOI: 10.1159/000109968.
  24. van der Weerd NC, Grooteman MP, Bots ML, et al. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One 2012;7(7):e39783. DOI: 10.1371/journal.pone.0039783.
  25. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012;23(10):1631–1634. DOI: 10.1681/ASN.2011111078.
  26. Besarab A, Ayyoub F. Anemia in renal disease. In: Schrier RW, ed. Diseases of the Kidney and Urinary Tract. Philadelphia: Lippincott Williams and Wilkins; 2007. pp. 2406–2430.
  27. Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164(6):659–663. DOI: 10.1001/archinte.164.6.659.
  28. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006;69(3):560–564. DOI: 10.1038/
  29. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17(4):1181–1191. DOI: 10.1681/ASN.2005090997.
  30. Singh N, Agarwal AK. Pumping iron: revisiting risks, benefits and strategies in treatment of iron deficiency in end-stage renal disease. Clin Nephrol 2012;77(3):188–194. DOI: 10.5414/CN107266.
  31. Thorp ML, Johnson ES, Yang X, et al. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology 2009;14(2): 240–246. DOI: 10.1111/j.1440-1797.2008.01065.x.
  32. Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009;4(1):33–38. DOI: 10.2215/CJN.00630208.
  33. Irwin C, Moriarity-Suggs C. Anemia management in chronic and end-stage kidney disease. US Pharma 2010;35(3)(Oncology/Hematology suppl):8–13.
  34. Pasricha SR. Is it time for hepcidin to join the diagnostic toolkit for iron deficiency? Expert Rev Hematol 2012;5:153–155. DOI: 10.1586/ehm.12.2.
  35. Locatelli F, Bárány P, Covic A, et al. Kidney Disease: Improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013;28(6):1346–1359. DOI: 10.1093/ndt/gft033.
  36. Cappellini MD, Comin-Colet J, de Francisco A, et al. Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management. Am J Hematol 2017;92(10):1068–1078. DOI: 10.1002/ajh.24820.
  37. Ratcliffe LE, Thomas W, Glen J, et al. Diagnosis and management of iron deficiency in CKD: a summary of the NICE guideline recommendations and their rationale. Am J Kidney Dis 2016;67(4):548–558. DOI: 10.1053/j.ajkd.2015.11.012.
  38. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012;2(1):279–335.
  39. Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One 2015;10(2):e0117383. DOI: 10.1371/journal.pone.0117383.
  40. KDOQI. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50(3):471–530. DOI: 10.1053/j.ajkd.2007.06.008.
  41. Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis 2013;62(5):849–859. DOI: 10.1053/j.ajkd.2013.06.008.
  42. Rozen-Zvi B, Gafter-Gvili A, Paul M, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008;52(5):897–906. DOI: 10.1053/j.ajkd.2008.05.033.
  43. Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 2015;90(1):12–23. DOI: 10.1016/j.mayocp.2014.10.007.
  44. Shepshelovich D, Rozen-Zvi B, Avni T, et al. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis. Am J Kidney Dis 2016;68(5):677–690. DOI: 10.1053/j.ajkd.2016.04.018.
  45. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif 2004;22(1):112–123. DOI: 10.1159/000074931.
  46. Thavarajah S, Choi MJ. The Use of Erythropoiesis-Stimulating Agents in Patients with CKD and Cancer: A Clinical Approach. Am J Kidney Dis 2019;74(5):667–674. DOI: 10.1053/j.ajkd.2019.04.022.
  47. Wish JB, Coyne DW. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. Mayo Clin Proc 2007;82(11):1371–1380. DOI: 10.4065/82.11.1371.
  48. Hayat A, Haria D, Salifu MO. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease. Patient Prefer Adherence 2008;2:195–200.
  49. Aapro M, Osterwalder B, Scherhag A, et al. Epoetin-β treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumor progression and thromboembolic events. Br J Cancer 2009;101(12):1961–1971. DOI: 10.1038/sj.bjc.6605255.
  50. Schaefer RM, Schaefer L. Iron monitoring and supplementation: how do we achieve the best results? Nephrol Dial Transplant 1998;13(90002 Suppl 2):9–12. DOI: 10.1093/ndt/13.suppl_2.9.
  51. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients’ response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol 2007;18(3):975–984. DOI: 10.1681/ASN.2006091034.
  52. Macdougall IC, White C, Anker SD, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 2019;380: 447–458. DOI: 10.1056/NEJMoa1810742.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.